Evaluation of Fibroblast Growth Factor Receptor 3 (FGFR3) and Tumor Protein P53 (TP53) as Independent Prognostic Biomarkers in High-Grade Non-muscle Invasive Bladder Cancer

Anil Kumar; Vivek K Singh; Vishwajeet Singh; Mukul K Singh; Ashustosh Shrivastava; Dinesh K Sahu

doi:10.7759/cureus.65816

journal article Jul 31, 2024

Evaluation of Fibroblast Growth Factor Receptor 3 (FGFR3) and Tumor Protein P53 (TP53) as Independent Prognostic Biomarkers in High-Grade Non-muscle Invasive Bladder Cancer

Anil Kumar

Vivek K Singh Vishwajeet Singh Mukul K Singh Ashustosh Shrivastava Dinesh K Sahu

Cureus · Springer Science and Business Media LLC

View at Publisher Save 10.7759/cureus.65816

Topics

No keywords indexed for this article. Browse by subject →

References

39

[1]

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021, 71:209-49. 10.3322/caac.21660 10.3322/caac.21660

[2]

Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: prostate and bladder tumours. Eur Urol. 2016, 70:106-19. 10.1016/j.eururo.2016.02.028 10.1016/j.eururo.2016.02.028

[3]

Cassell A, Yunusa B, Jalloh M, et al.. Non-muscle invasive bladder cancer: a review of the current trend in Africa. World J Oncol. 2019, 10:123-31. 10.14740/wjon1210 10.14740/wjon1210

[4]

Rice-Stitt T, Valencia-Guerrero A, Cornejo KM, Wu CL. Updates in histologic grading of urologic neoplasms. Arch Pathol Lab Med. 2020, 144:335-43. 10.5858/arpa.2019-0551-RA 10.5858/arpa.2019-0551-ra

[5]

Ilijazi D, Pulverer W, Ertl IE, et al.. Discovery of molecular DNA methylation-based biomarkers through genome-wide analysis of response patterns to BCG for bladder cancer. Cells. 2020, 9:1839. 10.3390/cells9081839 10.3390/cells9081839

[6]

Wang TH, Hsia SM, Shih YH, Shieh TM. Association of smoking, alcohol use, and betel quid chewing with epigenetic aberrations in cancers. Int J Mol Sci. 2017, 18:1210. 10.3390/ijms18061210 10.3390/ijms18061210

[7]

Petronis A. Epigenetics as a unifying principle in the aetiology of complex traits and diseases. Nature. 2010, 465:721-7. 10.1038/nature09230 10.1038/nature09230

[8]

Yatagai N, Saito T, Akazawa Y, et al.. TP53 inactivation and expression of methylation-associated proteins in gastric adenocarcinoma with enteroblastic differentiation. Virchows Arch. 2019, 474:315-24. 10.1007/s00428-018-2508-9 10.1007/s00428-018-2508-9

[9]

Lee KH, Song CG. Epigenetic regulation in bladder cancer: development of new prognostic targets and therapeutic implications. Transl Cancer Res. 2017, 6:677-68. 10.21037/tcr.2017.05.41 10.21037/tcr.2017.05.41

[10]

Schübeler D. Function and information content of DNA methylation. Nature. 2015, 517:321-6. 10.1038/nature14192 10.1038/nature14192

[11]

Bakkar AA, Wallerand H, Radvanyi F, et al.. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res. 2003, 63:8108-12.

[12]

Akanksha M, Sandhya S. Role of FGFR3 in urothelial carcinoma. Iran J Pathol. 2019, 14:148-55. 10.30699/IJP.14.2.148 10.30699/ijp.14.2.148

[13]

Bodoor K, Ghabkari A, Jaradat Z, et al.. FGFR3 mutational status and protein expression in patients with bladder cancer in a Jordanian population. Cancer Epidemiol. 2010, 34:724-32. 10.1016/j.canep.2010.05.003 10.1016/j.canep.2010.05.003

[14]

Targeting p53 pathways: mechanisms, structures and advances in therapy

Haolan Wang, Ming Guo, Hudie Wei et al.

Signal Transduction and Targeted Therapy 2023 10.1038/s41392-023-01347-1

[15]

Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res. 2000, 77:81-137. 10.1016/s0065-230x(08)60785-x 10.1016/s0065-230x(08)60785-x

[16]

Hollstein M, Hainaut P. Massively regulated genes: the example of TP53. J Pathol. 2010, 220:164-73. 10.1002/path.2637 10.1002/path.2637

[17]

Liyanage C, Wathupola A, Muraleetharan S, Perera K, Punyadeera C, Udagama P. Promoter hypermethylation of tumor-suppressor genes p16(INK4a), RASSF1A, TIMP3, and PCQAP/MED15 in salivary DNA as a quadruple biomarker panel for early detection of oral and oropharyngeal cancers. Biomolecules. 2019, 9:148. 10.3390/biom9040148 10.3390/biom9040148

[18]

Bhat S, Kabekkodu SP, Varghese VK, et al.. Aberrant gene-specific DNA methylation signature analysis in cervical cancer. Tumour Biol. 2017, 39:1010428317694573. 10.1177/1010428317694573 10.1177/1010428317694573

[19]

Bayramov B, Gunes S, Buyukalpelli R, Aydın O, Henkel R. Promoter methylation analysis of CDH1 and p14ARF genes in patients with urothelial bladder cancer. Onco Targets Ther. 2018, 11:4189-96. 10.2147/OTT.S158259 10.2147/ott.s158259

[20]

López JI, Angulo JC, Martín A, Sánchez-Chapado M, González-Corpas A, Colás B, Ropero S. A DNA hypermethylation profile reveals new potential biomarkers for the evaluation of prognosis in urothelial bladder cancer. APMIS. 2017, 125:787-96. 10.1111/apm.12719 10.1111/apm.12719

[21]

Siddiqui SA, Alshehri FA, Yaqinuddin A. Aberrant DNA methylation in bladder cancer among Saudi Arabia population. J Health Allied Sci NU. 2021, 11:164-9. 10.1055/s-0041-1726685 10.1055/s-0041-1726685

[22]

van Rhijn BW, van der Kwast TH, Liu L, et al.. The FGFR3 mutation is related to favorable pT1 bladder cancer. J Urol. 2012, 187:310-4. 10.1016/j.juro.2011.09.008 10.1016/j.juro.2011.09.008

[23]

Knowles MA. FGFR3 - a central player in bladder cancer pathogenesis?. Bladder Cancer. 2020, 6:403-23. 10.3233/BLC-200373 10.3233/blc-200373

[24]

Van Batavia J, Yamany T, Molotkov A, et al.. Bladder cancers arise from distinct urothelial sub-populations. Nat Cell Biol. 2014, 16:982-91. 10.1038/ncb3038 10.1038/ncb3038

[25]

Lamm D, Persad R, Brausi M, et al.. Defining progression in nonmuscle invasive bladder cancer: it is time for a new, standard definition. J Urol. 2014, 191:20-7. 10.1016/j.juro.2013.07.102 10.1016/j.juro.2013.07.102

[26]

Cambier S, Sylvester RJ, Collette L, et al.. EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance Bacillus Calmette-Guérin. Eur Urol. 2016, 69:60-9. 10.1016/j.eururo.2015.06.045 10.1016/j.eururo.2015.06.045

[27]

Mishra A, Singh N, Shyam H, et al.. Differential expression profiling of transcripts of IDH1, CEA, Cyfra21-1, and TPA in stage IIIa non-small cell lung cancer (NSCLC) of smokers and non-smokers cases with air quality index. Gene. 2021, 766:145151. 10.1016/j.gene.2020.145151 10.1016/j.gene.2020.145151

[28]

Catto JWF, Azzouzi AR, Rehman I, et al.. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol. 2005, 23:2903-10. 10.1200/JCO.2005.03.163 10.1200/jco.2005.03.163

[29]

Tomlinson DC, Baldo O, Harnden P, Knowles M. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol. 2007, 213:91-8. 10.1002/path.2207 10.1002/path.2207

[30]

Poyet C, Hermanns T, Zhong Q, et al.. Positive fibroblast growth factor receptor 3 immunoreactivity is associated with low-grade non-invasive urothelial bladder cancer. Oncol Lett. 2015, 10:2753-60. 10.3892/ol.2015.3691 10.3892/ol.2015.3691

[31]

Tanvir I, Hassan A, Albeladi F. DNA methylation and epigenetic events underlying renal cell carcinomas. Cureus. 2022, 14:e30743. 10.7759/cureus.30743 10.7759/cureus.30743

[32]

Zhang J, Xu R, Lu Q, et al.. A novel methylation marker NRN1 plus TERT and FGFR3 mutation using urine sediment enables the detection of urothelial bladder carcinoma. Cancers (Basel). 2023, 15:615. 10.3390/cancers15030615 10.3390/cancers15030615

[33]

Zheng YJ, Guo F, Zou Y, Jun W. Aberrant DNA methylation in P1 promoter region of TP53 gene in acute leukemia. J Leuk. 2017, 5:10.4172/2329-6917.1000227 10.4172/2329-6917.1000227

[34]

Jesionek-Kupnicka D, Szybka M, Malachowska B, et al.. TP53 promoter methylation in primary glioblastoma: relationship with TP53 mRNA and protein expression and mutation status. DNA Cell Biol. 2014, 33:217-26. 10.1089/dna.2013.2201 10.1089/dna.2013.2201

[35]

Saeed WH, Eissa AA, Al-Doski AA. Impact of TP53 gene promoter methylation on chronic lymphocytic leukemia pathogenesis and progression. J Blood Med. 2019, 10:399-404. 10.2147/JBM.S221707 10.2147/jbm.s221707

[36]

Borowczak J, Szczerbowski K, Maniewski M, et al.. The prognostic role of p53 and its correlation with CDK9 in urothelial carcinoma. Clin Transl Oncol. 2023, 25:830-40. 10.1007/s12094-022-02994-6 10.1007/s12094-022-02994-6

[37]

Bodoor K, Al-Ghabkari A, Matalka I, et al.. Assessment of p53 mutations, expression and prognosis in bladder cancer patients from Jordan: identification of novel deletion mutations in the DNA-binding domain. Meta Gene. 2017, 12:33-42. 10.1016/j.mgene.2017.01.002 10.1016/j.mgene.2017.01.002

[38]

Sikic D, Taubert H, Breyer J, et al.. The prognostic value of FGFR3 expression in patients with T1 non-muscle invasive bladder cancer. Cancer Manag Res. 2021, 13:6567-78. 10.2147/CMAR.S318893 10.2147/cmar.s318893

[39]

Kang W, Wang Q, Dai Y, et al.. Hypomethylation of PlncRNA-1 promoter enhances bladder cancer progression through the miR-136-5p/Smad3 axis. Cell Death Dis. 2020, 11:1038. 10.1038/s41419-020-03240-z 10.1038/s41419-020-03240-z

Metrics

1

Citations

39

References

Details

Published: Jul 31, 2024

Authors

A

Anil Kumar

Wadia Institute of Himalayan Geology

Ashustosh Shrivastava

D

Dinesh K Sahu

Cite This Article

Anil Kumar, Vivek K Singh, Vishwajeet Singh, et al. (2024). Evaluation of Fibroblast Growth Factor Receptor 3 (FGFR3) and Tumor Protein P53 (TP53) as Independent Prognostic Biomarkers in High-Grade Non-muscle Invasive Bladder Cancer. Cureus. https://doi.org/10.7759/cureus.65816

Evaluation of Fibroblast Growth Factor Receptor 3 (FGFR3) and Tumor Protein P53 (TP53) as Independent Prognostic Biomarkers in High-Grade Non-muscle Invasive Bladder Cancer

You May Also Like